{"id":"adynovi","safety":{"commonSideEffects":[{"rate":"null","effect":"Inj site reaction"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by replacing the deficient factor VIII in patients with hemophilia A, allowing for proper blood clotting. This helps to prevent and treat bleeding episodes, such as joint bleeds and muscle bleeds.","oneSentence":"ADYNOVI is a recombinant human coagulation factor VIII, used to treat and prevent bleeding episodes in patients with hemophilia A.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:07.594Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia A, prevention and treatment of bleeding episodes"}]},"trialDetails":[{"nctId":"NCT04158934","phase":"","title":"A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baxalta now part of Shire","startDate":"2020-07-09","conditions":"Hemophilia A","enrollment":207},{"nctId":"NCT05042440","phase":"PHASE1","title":"Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-08-11","conditions":"Hemophilia A","enrollment":13},{"nctId":"NCT02078427","phase":"","title":"ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-06-28","conditions":"Hemophilia A","enrollment":951},{"nctId":"NCT03006965","phase":"","title":"Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®","status":"COMPLETED","sponsor":"Spanish Society of Thrombosis and Haemostasis","startDate":"2016-11-11","conditions":"Hemophilia A, Hemophilia, Factor VIII Deficiency","enrollment":50},{"nctId":"NCT04015492","phase":"PHASE1","title":"Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-08-08","conditions":"Hemophilia A","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rurioctocog alfa pegol","rAHF-PEG"],"phase":"phase_2","status":"active","brandName":"ADYNOVI","genericName":"ADYNOVI","companyName":"Baxalta now part of Shire","companyId":"baxalta-now-part-of-shire","modality":"Biologic","firstApprovalDate":"","aiSummary":"ADYNOVI is a recombinant human coagulation factor VIII, used to treat and prevent bleeding episodes in patients with hemophilia A. Used for Hemophilia A, prevention and treatment of bleeding episodes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}